AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma - a Randomized, Open Label, 3 Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1R132H-specific Peptide Vaccine in Combination With Checkpoint Inhibitor Avelumab
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Avelumab (Primary) ; IDH1-SCA-VAC (Primary) ; Imiquimod
- Indications Glioma
- Focus Adverse reactions
- Acronyms AMPLIFY-NEOVAC
- 04 Jun 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
- 04 Jun 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
- 04 Jun 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.